Article

Nicox, B+L to co-promote glaucoma treatment in U.S.

Nicox S.A. has decided to exercise the option to co-promote its glaucoma and ocular hypertension treatment-latanoprostene bunod-with Bausch + Lomb in the United States.

 

Sophia Antipolis, France-Nicox S.A. has decided to exercise the option to co-promote its glaucoma and ocular hypertension treatment-latanoprostene bunod-with Bausch + Lomb in the United States.

The treatment was licensed by Nicox to Bausch + Lomb-a division of Valeant Pharmaceuticals International- in 2010. Under the agreement, Nicox was granted the option to co-promote the treatment in the United States.

More from this issue: Why immunomodulation is the next logical step in glaucoma control

Bausch + Lomb’s phase III clinical program-which is analyzing the nitric oxide (NO)-donating prostaglandin F2-alpha analog treatment-includes two studies, APOLLO and LUNAR, which are pivotal for registration in the United States, according to Nicox.

Valeant recently said that it expects to receive top-line efficacy results from the first of the phase III studies in the third quarter of 2014, and from the second of the studies in the fourth quarter. The company also said the treatment could be launched in the United States in 2016, pending approval from the FDA.

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
© 2025 MJH Life Sciences

All rights reserved.